The challenge of CDG diagnosis |
| |
Authors: | R. Francisco D. Marques-da-Silva S. Brasil C. Pascoal V. dos Reis Ferreira E. Morava J. Jaeken |
| |
Affiliation: | 1. UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal;2. Portuguese Association for CDG, Lisboa, Portugal;3. CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies – PPAIN), Portugal;4. Department of Clinical Genomics, CIM, Mayo Clinic, Rochester, MN, United States;5. Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium |
| |
Abstract: | Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement.This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis. |
| |
Keywords: | CDG Diagnosis MS NGS Whole Exome Sequencing Molecular testing AChR Acetylcholinesterase receptor ALP Alkaline phosphatase ALT Alanine aminotransferase ApoC-III Apolipoprotein C-III APPT Activated partial thromboplastin time AST Aspartate transaminase CDG Congenital Disorder(s) of Glycosylation CK (-MB) Creatine kinase (-Muscle/brain) CKP Creatine phosphokinase DAG Dystroglycan DHEA Dehydroepiandrosterone ERG Electroretinography FGF23 Fibroblast growth factor 23 FSH Follicle stimulating hormone GalNAc N-Acetylgalactosamine GlcNAc N-Acetylglucosamine GDP Guanosine diphosphate GPI Glycosylphosphatidylinositol ICAM1 Intercellular Adhesion Molecule 1 IEF Isoelectrofocusing QTOF Quadrupole time-of-flight LAMP2 Lysosome-associated membrane protein 2 LGMD Limb-girdle muscular dystrophy LLO Lipid-linked oligosaccharide LH Luteinizing hormone ManNAc MS Mass spectrometry NA Not applicable/not available NCAM1 Neural cell adhesion molecule 1 NGS Next generation sequencing NK Natural Killer PI-PLC Phosphoinositide-phospholipase C PHPV Persistent hyperplastic primary vitreous SA Sialic acid SLeX Sialyl-Lewis X Tf Transferrin UDP Uridine diphosphate VEP Visual evoked potentials WES Whole exome sequencing WGS Whole genome sequencing |
本文献已被 ScienceDirect 等数据库收录! |
|